Posizioni attive di Pablo Umaña
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Direttore Tecnico/Scientifico/R&S | 01/09/2000 | - |
| Fondatore | 01/09/2000 | - |
Storia della carriera di Pablo Umaña
Precedenti posizioni note di Pablo Umaña
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ROCHE HOLDING AG | Corporate Officer/Principal | - | - |
Statistiche
Distribuzione geografica
| Svizzera | 2 |
| Stati Uniti | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
| Corporate Officer/Principal | 1 |
Settori
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
| Aziende private | 1 |
|---|---|
Roche Glycart AG
Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Health Technology |
- Borsa valori
- Insiders
- Pablo Umaña
- Esperienza
